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Abstract
BACKGROUND—Randomized controlled trials (RCTs) in pediatric venous thromboembolism 
(VTE) treatment have been challenged by unsubstantiated design assumptions and/or poor accrual. 
Pilot/feasibility (P/F) studies are critical to future RCT success.
METHODS—Kids-DOTT is a multicenter RCT investigating non-inferiority of a 6-week 
(shortened) vs. 3-month (conventional) duration of anticoagulation in patients <21 years old with 
provoked venous thrombosis. Primary efficacy and safety endpoints are symptomatic recurrent 
VTE at 1 year and anticoagulant-related, clinically-relevant bleeding. In the P/F phase, 100 
participants were enrolled in an open, blinded endpoint, parallel-cohort RCT design.
RESULTS—No eligibility violations or randomization errors occurred. Of enrolled patients, 69% 
were randomized, 3% missed the randomization window, and 28% were followed in pre-specified 
observational cohorts for completely occlusive thrombosis or persistent antiphospholipid 
antibodies. Retention at 1 year was 82%. Inter-observer agreement between local vs. blinded 
central determination of venous occlusion by imaging at 6 weeks post-diagnosis was strong (κ-
statistic=0.75; 95% confidence interval [CI] 0.48–1.0). Primary efficacy and safety event rates 
were 3.3% (95% CI 0.3–11.5%) and 1.4% (0.03–7.4%).
CONCLUSIONS—The P/F phase of Kids-DOTT has demonstrated validity of vascular imaging 
findings of occlusion as a randomization criterion, and defined randomization, retention, and 
endpoint rates to inform the fully-powered RCT.
Keywords
thrombosis; child; anticoagulants; clinical trial; pilot study; reliability and validity
INTRODUCTION
Venous thromboembolism (VTE) has become a major pediatric health concern, largely as a 
consequence of invasive support and intensive care of ill children and improved survival of 
children with chronic illnesses. Of VTE in children, 90–95% is considered provoked, based 
on association with an identifiable, typically-transient risk factor such as surgery, central 
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venous catheterization, or hospitalization for exacerbation of a medical condition. The 
occurrence of VTE in hospitalized children has risen by 70% over 6 years to approximately 
1 in 200 [1], and the epidemic of obesity in children is anticipated to continue to amplify the 
problem and impact of VTE.
In both children and adults, treatment of VTE typically involves anticoagulation. However, 
none of the anticoagulants used in the routine clinical care of children with VTE is approved 
by federal regulatory agencies for this indication. Comorbidities and outcomes differ 
between children and middle-aged/elderly adults with VTE, yet recommendations for a 3-
month course of anticoagulation for pediatric patients with provoked VTE [2] have been 
based on results of clinical trials in adults [3]. Pediatric guidelines also suggest that 
consideration be given to a shorter, 6-week course of anticoagulation in certain scenarios, 
albeit without evidence.[2] Prolonged anticoagulation poses a considerable risk of bleeding 
complications in children, while inadequate treatment duration is associated with a risk of 
recurrent VTE. The net clinical benefit of a given duration of anticoagulation compared with 
another has not been evaluated in a pediatric population.
To address this issue in a generalizable fashion that will inform future guidelines and care in 
pediatric and young-adult VTE requires large, multicenter RCTs. In the past, investigator-
initiated trials involving prevention and/or treatment of pediatric venous or arterial 
thromboembolism were terminated due to futility or feasibility concerns [4–6]. This 
underscores the critical need for P/F studies to be conducted in order to validate design 
assumptions before executing fully-powered, definitive trials. Accordingly, the objective of 
the P/F phase of the Kids-DOTT trial was to evaluate, while maintaining the blind, key 
feasibility metrics and design assumptions on inter-observer reliability of radiological 
determination of venous occlusion, as well as recruitment, randomization, retention, 
protocol deviation, and endpoint rates.
PATIENTS AND METHODS
Study Design
The Kids-DOTT trial employs a parallel-cohort, randomized, open-label, blinded-endpoint 
(PROBE) design (www.clinicaltrials.gov NCT00687882) [7]. The primary aim of the trial is 
to compare the efficacy and safety of a three-month course versus a six-week course of 
anticoagulation for first-episode, provoked venous thrombosis in patients <21 years of age. 
A multicenter P/F phase was pre-specified to consist of the first 100 participants enrolled, 
with metrics described below. The Kids-DOTT trial was initially opened in 2007 at the 
University of Colorado (Aurora, CO, USA) with Institutional Review Board (IRB) approval 
as a limited, single-center pilot, with staged addition of further participating centers based 
upon Data and Safety Monitoring Committee reviews. From 2012–2013 the trial’s Clinical 
Coordinating Center was transitioned to All Children’s Hospital Johns Hopkins Medicine 
(ACH JHM, St. Petersburg, FL, USA). The study was approved by the local IRB at each 
participating site, with signed informed consent/assent required for patient participation. 
Recruitment in the P/F phase continued through December 2014, at which time the 100th 
participant was enrolled.
Goldenberg et al. Page 3
J Thromb Haemost. Author manuscript; available in PMC 2016 September 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Subject Eligibility
Inclusion criteria for the P/F phase were the same as for the main trial, and included: (1) age 
from birth (post-conceptional age ≥36 weeks) to <21 years; (2) radiologic evidence of 
venous or right atrial thrombosis within 30 days, and 3) identification of a provoking clinical 
factor at time of diagnosis or symptom onset (e.g.: recent hospitalization, immobilization, or 
traumatic injury; central venous catheterization; oral contraceptive pill administration; major 
infection). The inclusion of young adults <21 years old along with children was based on the 
appreciation that many pediatric hospitals and thrombosis centers (particularly in the U.S.) 
take responsibility for the management of these young adult patients; in addition, the 
protocol utilized the National Institute of Health age definition for pediatrics (e.g., Policy on 
Inclusion of Children) as <21 years of age, consistent with the trial’s early funding from the 
National Heart Lung and Blood Institute.
Exclusion criteria were: (1) prior VTE; (2) history of cancer; (3) congenital heart disease 
with history of single ventricle physiology or intra-cardiac shunt procedure; (4) known 
pulmonary embolism (other than septic embolism as in Lemierre’s syndrome, which was 
allowed); (5) thrombolytic therapy; (6) plasma antithrombin activity <30 IU/dL or protein C 
or S activity <20 IU/dL. Of note, prior to 2013 the exclusion criteria also included the 
presence of ≥3 thrombophilia traits (or 2 in the presence of a first-degree family history of 
young-onset VTE); given evolution of the standard of care at participating sites toward no 
longer performing comprehensive thrombophilia testing in provoked VTE, it was 
recommended at the annual Investigator Meeting that this exclusion criterion be removed 
from the protocol. Considering the absence of screen failures due multi-trait thrombophilia, 
as well as the opportunity to optimize trial design during the pre-specified P/F phase, the 
Steering Committee subsequently adopted (and Data and Safety Monitoring Committee 
endorsed) this recommendation.
Treatment and Observations
All participants received anticoagulant therapy in accordance with American College of 
Chest Physician guidelines [2,8]. The schedule of assessments is provided in Table 1. 
Randomization occurred at the 6 +/− 1 week follow-up visit given that the study intervention 
consists of stopping versus continuing anticoagulation after an initial 6 weeks of therapy, 
and in order to afford determination at the time of study intervention as to complete 
occlusion by repeat imaging and persistence of antiphospholipid antibodies (APA) by 
follow-up testing of previously positive APA values. Patients in whom flow was 
demonstrated in the previously-involved venous segment(s) and who were without persistent 
APA (APA) were randomized to stop anticoagulation after 6 weeks of therapy, versus 
continue anticoagulation for a total of 3 months. Randomization was executed via the trial’s 
vendor-hosted electronic data capture system (DATATRAK), utilizing a randomization code 
generated by a primary biostatistician and validated by an independent secondary 
biostatistician. Randomization was stratified by age group (<12 months, 12 months–<13 
years, 13–<21 years) and anatomic site of thrombosis (lower extremity DVT, upper 
extremity DVT, cerebral sinovenous thrombosis, other). As previously described for the trial 
design [7], patients not eligible for randomization at the 6 week visit were subsequently 
followed in non-randomized parallel observational cohorts defined by occlusive thrombosis 
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or persistent APA, due to lack of equipoise among prospective investigators for these 
subpopulations to potentially receive shortened-duration anticoagulation (i.e., perceived 
heightened risk of recurrent VTE).
All participants were followed for the primary safety endpoint of anticoagulant-associated 
clinically-relevant bleeding and primary efficacy endpoint of symptomatic recurrent VTE at 
1 year, in accordance with International Society on Thrombosis and Haemostasis (ISTH) 
Scientific and Standardization Committee (SSC) definitions for endpoints in pediatric VTE 
research [9]. A secondary endpoint of post-thrombotic syndrome (PTS) using the Manco-
Johnson instrument, as also described by the ISTH SSC [10,11].
Of note, the primary efficacy endpoint was initially defined at 2 years. However, in early 
2014, the Data and Safety Monitoring Committee noted an increasing trend in loss-to-
follow-up after the 1 year visit, and the Steering Committee then conducted a root cause 
analysis via survey of the participating site investigators. The principal cause was 
determined to be evolution in the standard of care toward discharge from follow-up after 1 
year among pediatric and young adult patients with provoked venous thrombosis. Given the 
opportunity to optimize trial design afforded by the pre-specified P/F phase, the Steering 
Committee then recommended (and the Data and Safety Monitoring Board endorsed) 
modification of the protocol to capture the primary and secondary efficacy endpoints at 1 
year. Endpoint definitions per se remained unchanged.
Quality Assurance
Quality assurance measures during the P/F phase included eligibility-type quality assurance 
and measurement-type quality assurance procedures. With regard to eligibility, the overall 
principal investigator performed real-time, remote source document verification of 
radiologic and laboratory reports from each subject’s medical record. This procedure was 
utilized to minimize the risk of protocol deviations pertaining to eligibility, enrollment and 
subsequent randomization. As for measurement-type quality assurance, participating sites 
obtained brief video files to document dynamically (rather than via static images alone) the 
apposition of the walls of the vein during compression ultrasonography with Doppler. This 
quality assurance measure was designed to optimize the reliability of, and inter-observer 
agreement in, the determination of complete venous occlusion by ultrasound.
P/F Metrics
P/F metrics were as follows: 1) screened: enrolled ratio; 2) accrual rate; 3) frequency of 
protocol violations pertaining to eligibility criteria and randomization procedures; 4) inter-
observer agreement in mutually blinded central versus local radiologist determination of 
presence/absence of complete veno-occlusion at 6 weeks post-diagnosis (a key 
randomization criterion); 5) proportion of the enrolled population comprising the non-
randomized parallel cohorts; 6) retention rate for primary endpoint assessment at 1 year 
post-diagnosis; and 7) estimates of endpoint rates in the RCT population.
Key protocol assumptions tested in the pilot/feasibility phase related to sample size and 
endpoint rates. For the definitive trial, a target sample size of 750 had been estimated to 
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achieve 285 participants retained to the 1-year primary endpoint in each randomized arm 
(accounting for per-protocol assignment of patients with occlusive thrombosis or persistent 
APA at 6 weeks to non-randomized parallel cohort arms, as well as for withdrawals/drop-
outs prior to 1 year [including withdrawals for eligibility violations or randomization 
errors]). Beyond their impact upon a feasibility metric of attrition, assessment of individual 
rates of randomization errors and protocol violations was left to the discretion of the 
Steering Committee toward its conclusion of trial feasibility. With respect to the analyzable 
RCT population, the protocol assumed a 25% attrition (non-randomizable proportion plus 
non-retention rate); these rate estimates had been developed and substantiated through early 
discussions of physician-investigator opinions and experiences at Investigators Meetings. 
Primary efficacy and safety endpoint rates were projected at 10% each, based upon 
evaluation of cumulative evidence from prior prospective research in the field, and 
estimation of clinically-relevant bleeding rate from published rates of major vs. minor 
bleeding. The Steering Committee determined that feasibility would be concluded if these 
protocol assumptions were upheld; in the case of endpoint rates, given the sample size of the 
pilot, we hypothesized that the 95% confidence interval of the observed rate for the primary 
efficacy and safety endpoints includes 10% each. (Formal net clinical benefit comparison of 
primary efficacy and safety endpoint rates between randomized arms was specified to occur 
at two formal interim analyses, conducted when n=200 and n=500 subjects reach the 1-year 
primary outcome assessment.) To conclude feasibility, the Steering Committee also required 
that the observed κ value for inter-observer agreement in radiological determination of 
occlusiveness exceed 0.7, based on a desire to indicate strong (“substantive”) agreement by 
Landis-Koch criteria [12].
Statistical analyses
Average recruitment rate was calculated based on the trial opening and closing dates at each 
clinical site. Descriptive analyses summarized frequencies with corresponding 95% 
confidence intervals (CIs), calculated by the Wald method. Inter-observer agreement was 
assessed by κ statistic.
RESULTS
Demographic characteristics, VTE-provoking factors, and distribution of thrombotic events 
by anatomic site in the 100 enrolled participants are shown in Table 2. The ratio of patients 
screened to enrolled was approximately 6:1, including declined consent in 4%. Sixty-nine 
percent of enrolled participants were randomized at the 6 +/− 1 week post-diagnosis visit 
(updated data at time of manuscript submission, 78%); 3% missed the randomization 
window. The remainder met criteria for non-random allocation at 6 weeks to parallel 
observational cohorts of complete veno-occlusion or persistent APA.
Following completion of an investigational drug sub-study of dalteparin [13], the average 
accrual was 0.18 (range: 0–0.76) participants per site per month, equivalent to an average 
accrual of 3.25 subjects per site per year. During this period of the trial, an average of 20 
participating centers were open. There were no eligibility violations or randomization errors. 
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Protocol deviations due to missed randomization were infrequent, occurring in 3% of 
children.
Anticoagulation therapy is summarized in Table 3 for the acute (first week) and sub-acute 
(beyond one week) periods prior to the randomization visit. During the acute phase, 
unfractionated heparin (UFH) or low molecular weight heparin (LMWH, mainly 
enoxaparin, but occasionally dalteparin under an investigator-held Investigational New Drug 
application with the U.S. Food and Drug Administration),[13]) were most often employed. 
In the sub-acute period, LMWH was principally administered, with the vitamin K antagonist 
(VKA) warfarin used in 3%.
In 86 participants, radiological images obtained at 6 weeks post-diagnosis were suitable for 
blinded central adjudication; images were not available from a small number of participating 
centers due to technical limitations in complying with IRB requirements pertaining to the 
transfer of these imaging files. Inter-observer agreement in the determination of complete 
veno- occlusion was 97% (95% CI, 89–99%). κ-statistic for inter-observer agreement was 
0.75 (95% CI, 0.48–1.0).
At the time of enrollment of the 100th patient on the trial (i.e., the pre-specified end of the 
pilot/feasibility phase), 73 participants had come due for the one-year endpoint visit, and the 
remaining 27 were not yet due for this visit. Among these 73, 60 completed a 1-year follow-
up visit, resulting in a retention of 82% to the primary endpoint. The primary efficacy 
endpoint, symptomatic recurrent VTE at 1 year, was 3.3% (95% CI: 0.3–11.5%) in the 
randomized population. Anticoagulant-associated clinically-relevant bleeding, the primary 
safety endpoint, occurred in 1.4% (0.03–7.4%). Two percent (95% CI: 0.1–11.5%) of 
patients (1/46) with limb DVT were diagnosed with clinically-significant PTS (a secondary 
efficacy endpoint) upon assessment at 1 year, and an additional 13% (6/46) had non-
clinically-significant PTS.
DISCUSSION
Our findings reported here from the P/F phase of the Kids-DOTT trial demonstrate the 
feasibility of identifying, enrolling, randomizing, and retaining pediatric and young adult 
patients in a multicenter RCT of VTE treatment, consisting of differing durations of 
anticoagulation. Protocol violations pertaining to eligibility or randomization were rare, 
confirming the effectiveness of the trial’s quality assurance measures. Additionally, we 
found strong inter-observer agreement in the radiologic assessment of complete venous 
occlusion 6-weeks following initial diagnosis of VTE. Lastly, we determined primary 
efficacy and safety endpoint rates of 3.3% and 1.4% for symptomatic recurrent VTE and 
anticoagulant-associated bleeding, respectively, during the first year.
These findings confirm the Kids-DOTT design, based on a total sample size of 
approximately 800 patients (originally specified as 750, now revised with these data to 815), 
whose recruitment at 42 participating sites will be completed over a 4-year accrual period 
(enrollment of final patient estimated to be Summer 2019), to test the hypothesis of non-
inferiority of a 6 week vs. 3 month duration of anticoagulation for provoked venous 
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thrombosis in patients <21 years old. Expansion to include international sites will enhance 
external validity (generalizability) and the potential to influence the standard of care for 
duration of anticoagulation in this population. As of early April 2015, 150 patients have 
been enrolled.
While awaiting the findings from the definitive trial, the P/F phase of Kids-DOTT provides 
among the most extensive RCT experience reported to date in the management of pediatric 
VTE, both in terms of the number of participating sites and size of the study population. In 
addition, the P/F findings from Kids-DOTT provide unique data on validity of radiologic 
assessment of complete venous occlusion, with implications for future research in the field. 
Given prior knowledge that the compression maneuver is critical to the diagnostic 
performance of compression ultrasonography for DVT [14], it is likely that the capture of 
brief dynamic video imaging during compression ultrasonography with Doppler contributed 
substantively to our findings of high inter-rater reliability. Similarly, we attribute the paucity 
of protocol deviations related to eligibility violations at least in part to the real-time, remote 
source document verification as an additional key quality assurance measure that will be 
maintained during the main Kids-DOTT trial.
Though bounded by wide confidence intervals, preliminary observations of symptomatic 
recurrent VTE and clinically-relevant bleeding event rates in this P/F phase of the Kids-
DOTT trial are low in comparison with findings in the Canadian REVIVE trial conducted in 
the 1990s--the only other published RCT of pediatric VTE treatment. REVIVE evaluated the 
LMWH reviparin, versus UFH followed by VKA, in the three-month treatment of a first 
VTE (provoked or unprovoked) in children aged >3 months and <18 years. Among 78 
children enrolled prior to early closure of the trial for poor accrual, the cumulative 
incidences of recurrent VTE (including both symptomatic and asymptomatic events) and 
major bleeding at 6 months post-diagnosis were each approximately 6% for reviparin, as 
compared to nearly 13% each for UFH/VKA. A number of non-randomized, uncontrolled 
trials have been reported, predominantly phase 2 studies of specific anticoagulants [15–18], 
providing additional insight about short-term risks of recurrent VTE and major/clinically-
relevant bleeding that were concordant with the one-year risks reported here for Kids-
DOTT. Notably, given that neither REVIVE nor non-randomized trials to date have 
employed PTS as an additional endpoint, the PTS findings from the P/F phase of Kids-
DOTT represent unique trial-derived data on PTS in children.
Limitations of the present work include the fact that recruitment assessment is limited to this 
the most informative time period during the P/F phase when the investigational drug sub-
study had been completed and most but not all of the planned centers were open and active. 
This may have led to an imprecise estimate of future accrual. In addition, the low event rates 
present a limitation and challenge for the main trial. While the 95% CI for the observed risk 
of recurrent VTE from the P/F phase included a value of 10% (the assumption in the 
protocol), the upper bound of the 95% CI for the observed risk of clinically relevant 
bleeding was a bit lower than 10%. Despite this finding, and recognizing that this was the 
only assumption not met in the P/F study and that this endpoint estimate was still imprecise 
due to the relatively small sample size to date, the Steering Committee determined that the 
trial should proceed directly into the “rest-of-trial” phase. However, as a consequence of the 
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low event rates, the Steering Committee and lead trial biostatistician (JMK) are working 
with the Data and Safety Monitoring Committee to develop additional stopping criteria 
pertaining to low event rates in the statistical analysis plan for the two pre-specified interim 
analyses, should these event rates continue to be low as the main trial expands. These 
stopping criteria will employ the bivariate endpoint analysis model described previously for 
the Kids-DOTT trial interim analyses [19]. A third limitation of the study is participant 
retention to the primary endpoint, which (at 82%) should be improved. Accordingly, the 
Clinical Coordinating Center is working with sites to adopt additional quality assurance 
measures, including heightened surveillance of enrolled subjects’ electronic health record 
for events that should prompt study endpoint visits, and approaches to enhanced adherence 
to long-term follow-up visits (including participant remuneration for travel/time). Lastly, the 
fact that a few of the eligibility criteria, as well as the long-term follow-up visit selected for 
the primary endpoint, were refined over time may be construed as a weakness of the trial. 
However, these adaptations were carefully reviewed by the Steering Committee and the 
Data and Safety Monitoring Committee prior to implementation, in order to assure that they 
did not substantively alter the enrolled population, and we believe that this ability to refine 
the trial is a key advantage of having pre-specified this P/F phase within the overall trial 
design.
Notwithstanding these limitations, the P/F phase of the Kids-DOTT trial provides a key 
contribution to the VTE field in demonstrating validity of vascular imaging findings of 
occlusion. It has also defined recruitment, randomization, retention, and endpoint rates to 
inform the fully-powered trial on duration of anticoagulation for provoked venous 
thrombosis in patients <21 years old. Regardless of its results, successful completion of the 
main trial will inform the standard of care for this growing population, toward achieving 
optimal outcomes.
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APPENDIX
Kids-DOTT participating site Principal Investigators who contributed data on enrolled 
patients during the P/F phase were as follows (alphabetically by site): All Children’s 
Hospital Johns Hopkins Medicine (N. Goldenberg), Blood Center of Wisconsin (R. 
Punzalan), Children’s Hospital Colorado/University of Colorado Denver (M. Wang/N. 
Goldenberg), Children’s Hospital of Los Angeles (J. Jaffray/G. Young), Children’s Hospital 
of Michigan/Wayne State University (M. Rajpurkar), Children’s Mercy Hospitals (S. 
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Carpenter), Children’s National Medical Center/George Washington University (Y. Diab/N. 
Verdun), Cincinnati Children’s Hospital Medical Center (C. Tarango), Cohen Children’s 
Medical Center (S. Acharya), Cook Children’s Medical Center (M. Torres), New York-
Presbyterian/Weill Cornell Medical Center (N. Kucine/B. Mitchell), Duke University 
Medical Center (N. Shah/C. Thornburg), Johns Hopkins Bloomberg Children’s Center (C. 
Takemoto), Michigan State University (R. Kulkarni), Nationwide Children’s Hospital (S. 
O’Brien), Oregon Health & Science University (K. Haley/M. Recht), Phoenix Children’s 
Hospital (C. Knoll), Rady Children’s Hospital (C. Thornburg/A. Geddis), Rainbow Babies 
and Children’s Hospital (S. Ahuja), Rush University Medical Center (M. Simpson), Texas 
Children’s Hospital/Baylor University (L. Srivaths), and University of Texas Southwestern/ 
Children’s Medical Center Dallas (J. Journeycake/A. Zia).
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Figure 1. 
Flow-diagram reflecting screened and enrolled populations and disposition of enrolled 
subjects over the course randomization and follow-up.
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Table 2
Demographic characteristics, distribution of index venous thrombotic events by anatomic site, and relationship 
of thrombosis to central venous catheterization in the randomized and non-randomized (parallel cohort) study 
populations.
Variable
Randomized
(N=69)
Not Randomized
(N=31) Total (N=100)
Sex
  Male N (%) 39 (56.5) 20 (64.5) 59 (59.0)
  Female 30 (43.5) 11 (35.5) 41 (41.0)
Ethnicity
  Hispanic N (%) 12 (17.4) 7 (22.6) 19 (19.0)
  Non-Hispanic 56 (81.2) 21 (67.7) 77 (77.0)
  Unknown 1 (1.4) 3 (9.7) 4 (4.0)
Race
  White N (%) 50 (72.5) 24 (77.4) 74 (74.0)
  Black 10 (14.5) 5 (16.1) 15 (15.0)
  Other Race 6 (8.7) 1 (3.2) 7 (7.0)
  Asian 2 (2.9) 0 (0.0) 2 (2.0)
  American Indian 0 (0.0) 1 (3.2) 1 (1.0)
  Unknown 1 (1.4) 0 (0.0) 1 (1.0)
Age at Enrollment
  Years* N 69 31 100
Mean (SD) 7.9 (7.0) 7.8 (7.6) 7.9 (7.1)
Index Thrombosis Anatomical Site
LE DVT N (%) 27 (39.1) 19 (61.3) 46 (46.0)
  UE DVT 17 (24.6) 5 (16.1) 22 (22.0)
CSVT 18 (26.1) 2 (6.5) 20 (20.0)
  Other 7 (10.1) 5 (16.1) 12 (12.0)
Index Thrombosis Catheter-Related
  Yes N (%) 32 (46.4) 14 (45.2) 46 (46.0)
  No 37 (53.6) 17 (54.8) 54 (54.0)
*
Data were parametrically (i.e., normally) distributed.
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Table 3
Anticoagulant agent use in the randomized population, by acute (first week) and sub-acute (after first week) 
period post-diagnosis of index venous thrombotic event.
Acute period
  LMWH N (%) 43 (67.2)
  UFH 20 (31.3)
  Other* 1 (1.6)
Sub-acute period
  LMWH N (%) 62 (95.4.9)
  Warfarin 2 (3.1)
  Other* 1 (1.5)
Abbreviations: LMWH, low molecular weight heparin; UFH, unfractionated heparin.
*Consisted of fondaparinux.
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